Evidence map›Paper›PMID 41226668›Full record

ArticleInternational journal of molecular sciences2025

Manipulation with Mutational Status of VHL Regulates Hypoxic Metabolism and Pro-Angiogenic Phenotypes in ccRCC Caki-1 Cells.

Pavel Abramov, Alexandr Mazur, Aleksey Starshin, Svetlana Zhenilo, Egor Prokhortchouk

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Pavel AbramovFederal Research Centre «Fundamentals of Biotechnology», Russian Academy of Sciences, 119071 Moscow, Russia.ORCID 0000-0002-7995-3490
Alexandr MazurFederal Research Centre «Fundamentals of Biotechnology», Russian Academy of Sciences, 119071 Moscow, Russia.
Aleksey StarshinFederal Research Centre «Fundamentals of Biotechnology», Russian Academy of Sciences, 119071 Moscow, Russia.ORCID 0000-0002-4965-0165
Svetlana ZheniloFederal Research Centre «Fundamentals of Biotechnology», Russian Academy of Sciences, 119071 Moscow, Russia.ORCID 0000-0003-0874-1594
Egor ProkhortchoukFederal Research Centre «Fundamentals of Biotechnology», Russian Academy of Sciences, 119071 Moscow, Russia.ORCID 0000-0001-8234-9975

Funding

Russian Science Foundation 19-74-30026Sirius University of Science and Technology Agreement № 21-03 date 27.09.2024
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC), accounting for 80-90% of renal malignancies, is frequently driven by VHL inactivation-either through mutation or promoter hypermethylation-resulting in constitutive HIF2α activation and pseudohypoxic signaling. VHL gene inactivation is a hallmark of von Hippel-Lindau syndrome, a hereditary disorder predisposing patients to ccRCC and other tumors, underscoring its central role in disease pathogenesis. While VHL dysfunction promotes aggressive tumor phenotypes, the therapeutic potential of VHL restoration remains underexplored. Here, using the Cas9 induced VHL-mutation in the Caki-1 cell line model, we demonstrate that VHL inactivation augments hypoxia-like pathways and enhances anaerobic glycolysis. Rescue of functional VHL reversed these activation patterns and modulated the expression of genes associated with angiogenesis. Using single cell transcriptomics, we show that the VHL-positive and -negative Caki-1 cells are characterized with different proportions of benign and aggressive cells as seen by analysis of specific gene expression. Furthermore, the identified angiogenesis-related genes were linked to affect clinical outcomes in ccRCC patients, suggesting that VHL restoration may mitigate high-risk molecular features.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsMutationNeovascularization, PathologicVon Hippel-Lindau Tumor Suppressor ProteinCell Line, TumorGene Expression Regulation, NeoplasticGlycolysisHumansPhenotypeVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteinhypoxiarenal cancersingle-cellVHL

Identifiers

PMID41226668
PMCPMC12608846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.